[go: up one dir, main page]

MX2018003699A - Moduladores de tlr y metodos de uso. - Google Patents

Moduladores de tlr y metodos de uso.

Info

Publication number
MX2018003699A
MX2018003699A MX2018003699A MX2018003699A MX2018003699A MX 2018003699 A MX2018003699 A MX 2018003699A MX 2018003699 A MX2018003699 A MX 2018003699A MX 2018003699 A MX2018003699 A MX 2018003699A MX 2018003699 A MX2018003699 A MX 2018003699A
Authority
MX
Mexico
Prior art keywords
methods
tlr modulators
tlr
combinations
modulators
Prior art date
Application number
MX2018003699A
Other languages
English (en)
Inventor
Scott Barden Horan Gerald
Original Assignee
Celgene Alpine Invest Company Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Alpine Invest Company Ii Llc filed Critical Celgene Alpine Invest Company Ii Llc
Publication of MX2018003699A publication Critical patent/MX2018003699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se describen combinaciones que comprenden un oligonucleótido SMAD7 y un modulador de receptor tipo Toll (TLR). También se proporcionan en la presente métodos para el uso de tales combinaciones para tratar las condiciones de una enfermedad, inclusive trastornos inflamatorios, tales como la enfermedad inflamatoria intestinal (IBD).
MX2018003699A 2015-09-30 2016-09-30 Moduladores de tlr y metodos de uso. MX2018003699A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235475P 2015-09-30 2015-09-30
US201662360256P 2016-07-08 2016-07-08
PCT/US2016/054734 WO2017059225A1 (en) 2015-09-30 2016-09-30 Tlr modulators and methods of use

Publications (1)

Publication Number Publication Date
MX2018003699A true MX2018003699A (es) 2018-08-01

Family

ID=58427899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003699A MX2018003699A (es) 2015-09-30 2016-09-30 Moduladores de tlr y metodos de uso.

Country Status (6)

Country Link
US (1) US20180289692A1 (es)
EP (1) EP3356530A4 (es)
JP (1) JP2018529726A (es)
CA (1) CA3000195A1 (es)
MX (1) MX2018003699A (es)
WO (1) WO2017059225A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
US10517889B2 (en) * 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
CN108310371B (zh) * 2018-03-09 2020-06-09 广州铭康生物工程有限公司 一种降血脂药物组合物及其用途
WO2019226361A1 (en) 2018-05-25 2019-11-28 Ramji Anant Methods for testing for food allergies and allergens in foods
CN113811312A (zh) * 2019-01-08 2021-12-17 阿伏伽德罗开发公司 脂肪性肝病的治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
CA2465948A1 (en) * 2001-11-09 2003-05-15 Lauren Charous A method for treating inflammatory bowel disease
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
CA2848595A1 (en) * 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
MX363746B (es) * 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
JP2016540013A (ja) * 2013-12-13 2016-12-22 武田薬品工業株式会社 Ｔｌｒ阻害剤としてのピロロ［３，２−ｃ］ピリジン誘導体
WO2015011694A2 (en) * 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides

Also Published As

Publication number Publication date
EP3356530A1 (en) 2018-08-08
WO2017059225A1 (en) 2017-04-06
JP2018529726A (ja) 2018-10-11
US20180289692A1 (en) 2018-10-11
EP3356530A4 (en) 2019-04-10
CA3000195A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
MX2018003699A (es) Moduladores de tlr y metodos de uso.
IL269725B (en) Use of glucocorticoid receptor modulators to treat cervical cancer
MA39741A (fr) Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
PH12014501914A1 (en) Anti sez6 antibodies and methods of use
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
MY175665A (en) Compositions for modulating sod-1 expression
NZ755605A (en) Compositions for modulating tau expression
MX2015005831A (es) Antagonistas de il-6 y usos de los mismos.
GT201700062A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
MX2017000135A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
EA201790802A1 (ru) Соединения против tnf
EP4035664A3 (en) Treating cancer using selective estrogen receptor modulators
MX2017005797A (es) Receptores quimericos de antigeno anti-cldn y metodos de uso.
MX373283B (es) Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento.
MY173880A (en) Novel modulators and methods of use
MX2015012334A (es) Metodos y composiciones para el control de malezas.
ZA201702403B (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
ECSP17040003A (es) Métodos para utilizar oligonucleótidos antisentido para smad7
ZA201701526B (en) Methods of treating depression using nmda modulators
ZA201705305B (en) Microcapsules imparting intense vanilla odor note
IL250849A0 (en) Methods for preparing toll-like receptor modulators
MX2016003248A (es) Metodos de uso de anticuerpos anti-lgr5.
HK1238136A1 (en) Methods of treating depression using nmda modulators